Baseline demographic, clinical, biochemical, functional, quality of life and imaging characteristics. All values are median (first quartile to third quartile) unless otherwise stated
| Characteristic | Patients (n=93) |
|---|---|
| Age mean (95% CI) | 56.6 (53.9 to 59.4) |
| Female n (%) | 63/93 (67.7) |
| Duration of RA (years) | 7.0 (4.5–9.5) |
| Duration of remission (months) | 22 (12–34) |
| DMARD therapy | |
| No treatment | 9 |
| Methotrexate only | 37 |
| Sulphasalazine only | 22 |
| Leflunomide only | 4 |
| Hydroxychloroquine only | 2 |
| Gold only | 2 |
| Combination dual therapy | 12 |
| Combination triple therapy | 5 |
| RF positive n (%) | 39/93 (41.9) |
| Anti-CCP positive n (%) | 38/64 (59.4) |
| Shared epitope positive n (%) | 55/91 (60.4) |
| XR erosion present n (%) | 70/85 (82.4) |
| HAQ-DI score mean (95% CI) | 0.337 (0.277 to 0.397) |
| RAQoL mean (95% CI) | 6.4 (5.3 to 7.6) |
| TJC28>1 n (%) | 25/93 (26.9) |
| SJC28>1 n (%) | 39/93 (41.9) |
| CRP>0 n (%) | 51/93 (54.8) |
| TJC28 | 0 (0–2) |
| SJC28 | 1 (0–4) |
| CRP | 5 (0–8) |
| DAS28 | 2.29 (1.79–3.19) |
| SDAI | 6.1 (3.0–9.1) |
| SDAI remission n (%) | 31/93 (33.3) |
| DAS28 remission n (%) | 52/93 (55.9) |
| 1981 ACR remission n (%) | 50/93 (53.8) |
| 2011 ACR/ EULAR remission n (%) | 13/93 (14.0) |
| Number of patients with US GS synovial hypertrophy | 83/93 (89.2%) |
| Number of joints with US GS synovial hypertrophy per patient (/8) | 3 (2–5) |
| Number of patients with PD activity | 58/93 (62.4%) |
| Number of joints with PD activity per patient (/8) | 1 (0–2) |
| Number of patients with US erosions present | 65/93 (69.9%) |
ACR, American College of Rheumatology; Anti-CCP, anticitrullinated protein antibody; CRP, C reactive protein; DAS28, 28-joint count Disease Activity Score; DMARD, disease-modifying antirheumatic drugs; EULAR, European League Against Rheumatism; HAQ-DI, Health Assessment Questionnaire Disability Index; PD, ultrasound power Doppler; RA, rheumatoid arthritis; RAQoL, RA Quality of Life Questionnaire score; RF, rheumatoid factor; SDAI, Simplified Disease Activity Index; SJC28, swollen 28-joint count; TJC28, tender 28-joint count; US, ultrasound; US GS, ultrasound Grey Scale; XR, x-ray.